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Abstract
Background: NUT midline carcinoma (NMC) is a rare and highly aggressive malignancy. Although more
information on NMC has been recently accumulating in the literature, most oncologists and pathologists remain
unfamiliar with the clinical and pathologic features of this disease. The clinical features of NMC sometimes mimic
those of other malignancies, and NMC can therefore be overlooked if the diagnosis is not suspected. We present
the case of a young male with NMC arising in the mediastinum with elevated serum alpha-fetoprotein levels
suggestive of an extragonadal nonseminomatous germ-cell tumor.
Case presentation: A 28-year-old Japanese male presented with cough and left-sided chest pain for 6 weeks. The
patient had a mediastinal tumor with metastases to the right lung, lymph nodes, and bones at initial presentation.
Nonseminomatous germ cell tumor was suspected due to the young age, location of the tumors, and elevated
serum alpha-fetoprotein. However, biopsy confirmed the diagnosis of NMC with immunohistochemistry. The tumor
briefly responded to cytotoxic chemotherapy but subsequently progressed and became refractory to the
chemotherapy regimen. External beam radiotherapy was administered with dramatic shrinkage of the tumor and a
metabolic response on 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG
PET/CT) scan. However, the patient died 4.5 months after the diagnosis of NMC.
Conclusions: Serum levels of alpha-fetoprotein may be elevated in patients with NMC. Regardless of the level of
tumor markers, immunohistochemistry for NUT should be performed in cases of poorly differentiated carcinomas
without glandular differentiation arising in the midline structures. 18F-FDG PET/CT is useful for staging and assessing
responses to therapy.
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Background
NUT midline carcinoma (NMC) is a highly aggressive
subset of squamous cell carcinomas, affecting both chil-
dren and adults [1]. The genetic hallmark is a rearrange-
ment of the NUT gene, located on chromosome 15 [2].
The rearrangement commonly occurs between the NUT
gene and BET family genes BRD4 and BRD3 [1], al-
though other rare fusion partners of the NUT gene have
also been recently reported [3].
Because of the poor prognosis (median survival
6.7 months) [2] and poor response to conventional
cytotoxic chemotherapy, new drugs such as BET inhibi-
tor (BETi) and histone deacetylase inhibitor (HDACi)
are now in clinical trials for patients with NMC [3].
Because of the availability of these potentially promising
new investigational drugs, prompt diagnosis of NMC is
even more important to plan appropriate treatment and
to encourage patients to consider participating in clinical
trials. Most oncologists and pathologists are not familiar
with NMC owing to its rarity. The clinical features of
NMC sometimes mimic those of other malignancies. For
these reasons, NMC may often be misdiagnosed if it is
not suspected and specifically looked for. In one study,
114 cases of poorly differentiated carcinomas or unclas-
sified mediastinal malignancies were pathologically
reexamined using immunohistochemistry for NUT and
fluorescence in situ hybridization (FISH), leading to the
diagnosis of NMC in 4 (3.5%) cases [4]. Here we report
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the case of a young male with NMC arising in the medi-
astinum with elevated serum alpha-fetoprotein (AFP)
levels, suggestive of an extra-gonadal nonseminomatous
germ cell tumor (NSGCT).
Case presentation
A 28-year-old Japanese male presented with cough and
left-sided chest pain for 6 weeks. The medical, surgical,
and family histories were unremarkable. He smoked
approximately 20 cigarettes per day for 6 years and in-
frequently consumed small amounts of alcohol. Physical
examination was unremarkable; the lungs were clear to
auscultation. Chest X-ray revealed an enlarged mediasti-
num. A full-body CT scan showed a bulky mediastinal
mass with right bronchial stenosis, lymphadenopathy in
the right side of the hilum and supraclavicular region,
and a mass in the right middle lobe measuring 4.4 ×
3.0 cm (Fig. 1). 18F-FDG PET/CT showed the involve-
ment of multiple bones, including spine, scapula, ribs,
sternum, pelvis, and femur (Fig. 2a).
The clinical course and patient background suggested a
differential diagnosis that included lung cancer, lymphoma,
and a mediastinal germ cell tumor (GCT). Laboratory in-
vestigations were significant for an elevated serum lactate
dehydrogenase [LDH; 667 IU/L (normal range: 119–
229 IU/L)], C-reactive protein [0.82 mg/dL (0.01–0.4 mg/
dL)], soluble IL-2 receptor [770 U/mL (112–496 U/mL)],
and AFP [163.8 ng/mL (0–20 ng/mL)]. Serum levels of β-
human chorionic gonadotropin (β-hCG), carcinoembryonic
antigen, pro-gastrin-releasing peptide, and cytokeratin-19
fragments (CYFRA) were within normal limits.
Pathology examination of tissue from an endobronchial
ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA) biopsy of a mediastinal lymph node
revealed a loosely cohesive growth pattern with prominent
necrosis and degeneration and no clear pattern of differ-
entiation (Fig. 3a). The tumor was composed of ovoid and
spindle-shaped cells with anisocytosis, scanty cytoplasm,
and irregular ovoid hyperchromatic nuclei (Fig. 3b).
Only a minor proportion (<5%) of the cells were positive
for AE1/AE3. Squamous cell markers (p40 and p63) were
weakly positive in 10–20% of the cells. Neuroendocrine
markers (chromogranin and synaptophysin), leukocyte
common antigen, myogenic markers (MyoD1 and myo-
genin), germ cell markers (placental alkaline phosphatase
and hCG), c-kit, TTF-1, CA19-9, and CD30 were all nega-
tive. The surface markers of tumor cells obtained with
flow cytometry were not compatible with lymphoma. A
bone marrow aspiration and biopsy revealed infiltration of
cells with pathologic features similar to those of the
EBUS-TBNA biopsy specimen.
The clinical presentation of a mediastinal tumor in a
young male with an elevated serum AFP suggested
NSGCT, but findings of immunohistochemistry of
tumor sections were not consistent with that diagnosis.
An outside pathology consultation was obtained, and the
diagnosis of NMC was suggested due to the pathologic
and clinical characteristics. Thus, immunohistochemistry
using NUT (C52B1) rabbit monoclonal antibody was
performed.
While waiting for results of the immunohistochemical
examination for NUT, serum levels of LDH increased to
993 IU/L on day 11, suggesting rapid disease progres-
sion. Because of the poorly differentiated pattern on
histologic analysis, elevated serum AFP, and case reports
indicating that cisplatin-based treatment showed some
efficacy for treating NMC [5], we decided to start
chemotherapy with BEP regimen (bleomycin 30 kU on
days 1, 8, and 15; etoposide, 100 mg/m2 on days 1–5;
and cisplatin, 20 mg/m2 on days 1–5; given every
21 days). On day 8 of the first cycle, the immunohisto-
chemistry result revealed that most of the neoplastic cell
nuclei were strongly positive for NUT in a speckled
pattern (Fig. 3c). The diagnosis of NMC was thus con-
firmed. After two cycles of chemotherapy, CT showed
tumor regression, and serum levels of LDH declined.
Therefore, the BEP regimen was continued. However,
after three cycles, CT showed tumor progression.
Because the performance status of the patient had
declined, we considered single-agent chemotherapy to
be most appropriate and started doxorubicin (75 mg/m2
every 21 days). Despite the change in chemotherapy
regimen, serum levels of LDH continued to increase.
Therefore, we judged doxorubicin to be ineffective,
Fig. 1 Full-body CT scan at the first visit. Tumor in the mediastinum and lymphadenopathy in the right side of the hilum and supraclavicular
region (a). A tumor in the right middle lobe (b). Right bronchial stenosis due to the mediastinal tumor is shown (c)
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although CT scan after the first cycle of doxorubicin
showed no change in tumor volume. We believed that
local control of the mediastinal mass was most import-
ant for the patient at that point to prevent airway
obstruction as the tumor progressed. Some authors have
reported on the effectiveness of radiotherapy and
chemoradiotherapy for NMC [2, 6], we therefore admin-
istered mediastinal radiotherapy with concomitant
weekly docetaxel (30 mg/m2). Radiotherapy was planned
with conventional fractionation, 60 Gy/30 fractions (fr).
CT after 16 Gy had been administered showed an
apparent decrease in tumor bulk in the irradiated area,
although it had increased in other areas. Docetaxel did
not seem to be beneficial for systemic tumor control,
and platelet counts had decreased by 2.9 × 103/μL; thus,
docetaxel was discontinued after four cycles and radio-
therapy alone was continued. The patient started to
complain of pain in the lower back and right femur;
MRI confirmed the presence of osteolytic bone metasta-
ses. Palliative radiotherapy (30 Gy/10 fr) for metastases
in vertebrae L3–S1 and the right femur was concurrently
started with irradiation to the mediastinum. Although
the pain in the lower back and right femur were relieved,
the patient developed painless proptosis in the right eye.
While considering additional radiotherapy to prevent
pain, we performed 18F-FDG PET/CT to evaluate the
extent of metastases to the bones and other organs. It
showed that radiotherapy had achieved good local con-
trol in the mediastinum, vertebrae L3–S1, and right
femur, but there were many new sites of abnormal FDG
accumulation (Fig. 2b). Moreover, there was an abnor-
mal FDG uptake in a mass in the right orbital soft tissue
(Fig. 2c), suggestive of orbital metastasis. Since then, the
patient condition gradually deteriorated, and only pallia-
tive care was given. He died 4.5 months after the initial
diagnosis of NMC.
Fig. 2 a 18F-FDG PET/CT scan before chemotherapy, with abnormal FDG uptake seen in the mediastinal tumor and the right lung metastasis,
lymph nodes, and multiple bones (spine, scapula, ribs, sternum, pelvis, and femur). b 18F-FDG PET/CT scan after chemotherapy and radiotherapy
to the mediastinum, vertebrae L3–S1, and right femur, showing dramatic shrinkage of the tumor and improved metabolic response, while many
new abnormal FDG accumulations are demonstrated in other sites. c Abnormal FDG uptake in a mass in the right orbital soft tissues, suggestive
of orbital metastasis
Fig. 3 a Tumor section (H&E, 100×) with loosely arranged cells with evident necrosis and degeneration and no clear pattern of differentiation.
b The tumor is composed of ovoid and spindle-shaped cells with anisocytosis, scanty cytoplasm, and irregular ovoid hyperchromatic nuclei.
c Immunohistochemistry of tumor cell nuclei showing speckled staining for NUT
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Discussion
Except for the inconsistency with histologic results, the
characteristics of the present case for the most part
resembled those of extra-gonadal NSGCT: 1) occurrence
in young adults, mostly males; 2) midline location; 3)
metastases to the lungs, liver, and bones; and 4) elevated
serum tumor markers (AFP and hCG) [7].
In an international analysis of mediastinal nonsemino-
mas, an elevated serum AFP was present in 74% (211/
287) and β-hCG in 38% (110/287) of the cases [8]. The
serum AFP level of the present case was compatible with
those results. Aside from the present case, there are only
three case reports of NMC with elevated serum AFP
levels. In one case, the AFP level was 326 μg/L and β-
hCG was <1 IU/L [5]; in another case, they were 62 ng/
mL and N/A [9]; in the other, they were 1742 ng/mL
and <2 IU/L, respectively [10]. If immunohistochemistry
for NUT had not been performed, these cases may have
been classified as poorly differentiated carcinoma with
midline distribution (extra-gonadal germ cell syndrome),
one of the groups of carcinoma of unknown primary
with favorable prognosis [11].
French et al. [11] recommended that immunohisto-
chemistry for NUT should be performed in all poorly
differentiated carcinomas without glandular differentiation
arising in the chest, head, and neck. This means that even
if serum tumor markers for GCT are elevated in cases of a
tumor arising from such sites, NMC should be suspected.
Definitive diagnosis can be made only by demonstra-
tion of nuclear staining using the rabbit monoclonal
antibody (clone C52B1) for the NUT protein, even
without confirmation of the fusion oncogene with FISH.
The antibody is highly sensitive (87%) and specific
(100%) in non-GCTs [12]. Because we did not suspect
NMC initially and did not cryopreserve the pathology
specimen, we could not perform the additional molecu-
lar analyses such as FISH. It is noteworthy that GCTs
can also display nuclear NUT reactivity, but the staining
is very focal (<5% of tumor cells) and faint, and it lacks
the speckled pattern [13]. In one report, CD34 immuno-
reactivity was positive in 7 of 11 NMC cases despite they
were epithelial tumor [14]. We performed an additional
immunohistological staining of CD34 in the present case
after the patient’s death however, no significant CD34
staining was observed.
Another remarkable feature in the present case was
the metastasis to the orbital soft tissues. Only four
patients with NMC who had orbital involvement have
been reported [2, 15–17]. Although involvement of the
mediastinum, paranasal sinuses, nasal cavity, intra-
thoracic organs, bone, and lymph nodes have been com-
monly reported, intra-abdominal organs [5, 18] and
cutaneous tissue [19] are rare metastatic sites. Till date,
there has been no report of brain involvement [20].
The usefulness of 18F-FDG PET/CT has been demon-
strated in staging and assessing the response to treat-
ment of NMC [21, 22]. In our patient, 18F-FDG PET/CT
was performed before and after treatment, showing a
good response to radiation therapy by the tumor. Metas-
tasis to the bone marrow was shown with 18F-FDG PET/
CT, but not with CT alone. We therefore recommend
performing 18F-FDG PET/CT before treatment for
accurate staging of NMC.
As in other reports, the tumor in the present case
briefly responded to cytotoxic chemotherapy but became
refractory to the treatment soon after. There are no
specific effective chemotherapeutic regimens [2] because
even dose-dense chemotherapy was not found to control
the tumor for long [23]. It is probably impossible to cure
NMC with cytotoxic chemotherapy alone. Thus, novel
targeted therapeutic approaches such as BETi (direct
acting inhibitors of the BRD3 and BRD4 bromodomains)
and HDACi are highly anticipated [3]. Several phase I
clinical trials of BETi (GSK-525762A and OTX015) and
HDACi (CUDC-907) are available to patients with
NMC. Because of rapid tumor progression and only a
short-term response to cytotoxic chemotherapy, we
should encourage patients diagnosed with NMC to con-
sider participating in clinical trials as early as possible.
Conclusions
In summary, we present the case of a patient who had
clinical features similar to those of extra-gonadal
NSGCT. As serum levels of AFP can be elevated in
NMC, immunohistochemistry for NUT should be con-
sidered in all poorly differentiated carcinomas arising in
midline structures without glandular differentiation, re-
gardless of the levels of tumor markers. 18F-FDG PET/
CT is useful for staging and assessing the response to
therapy. It is expected that novel targeted therapies may
change the poor prognosis of NMC in the near future.
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